ZURA 4.90 Zura Bio Limited
| Range: | 2.0-6.35 | Vol Avg: | 466356 | Last Div: | 0 | Changes: | 0.03 |
| Beta: | 0.15 | Cap: | 0.31B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Tue Mar 21 2023 | Empoloyees: | 14 | ||
| CUSIP: | CIK: | 0001855644 | ISIN: | KYG9TY5A1016 | Country: | US | |
| CEO: | Mr. Robert Lisicki | Website: | https://zurabio.com | ||||
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.
Stock Details
ZURA 5
Zura Bio initiated with a Neutral at H.C. Wainwright
Mitchell Kapoor·Thu Sep 05 2024
H.C. Wainwright
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow